Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80


GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities.

Yang XC, Qian SJ, Wang L, Liao SD, Cao J, Hu YZ, He QJ, Zhu H, Yang B.

Transl Oncol. 2013 Feb;6(1):75-82. Epub 2013 Feb 1.


R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.

Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J.

Mol Cancer Ther. 2007 Feb;6(2):484-95.


MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison.

Xie CY, Zhu H, Lin LP, Miao ZH, Geng MY, Cai YJ, Chen Y, Zhao HJ, Luo HB, Zhang XW, Fan LM, Shen YM, Ding J.

Mol Cancer Ther. 2007 Nov;6(11):3059-70.


Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.

Chang JY, Guo X, Chen HX, Jiang Z, Fu Q, Wang HK, Bastow KF, Zhu XK, Guan J, Lee KH, Cheng YC.

Biochem Pharmacol. 2000 Mar 1;59(5):497-508.


Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.

Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T, Yamada Y.

Cancer Res. 1996 Jun 15;56(12):2809-14.


Potential usage of liposomal 4beta-aminoalkyl-4'-O-demethyl-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy.

Shimizu K, Takada M, Asai T, Irimura K, Baba K, Oku N.

Biol Pharm Bull. 2002 Jun;25(6):783-6.


Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA.

PLoS One. 2010 Apr 15;5(4):e10186. doi: 10.1371/journal.pone.0010186.


Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.

Kamal A, Suresh P, Ramaiah MJ, Mallareddy A, Imthiajali S, Pushpavalli SN, Lavanya A, Pal-Bhadra M.

Bioorg Med Chem. 2012 Mar 15;20(6):2054-66. doi: 10.1016/j.bmc.2012.01.039. Epub 2012 Feb 9.


A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K.

Cancer Sci. 2003 Jan;94(1):119-24.


Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.

Cancer Res. 1998 Apr 1;58(7):1460-8.


Novel carbamate derivatives of 4-beta-amino-4'-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation.

Duca M, Arimondo PB, Léonce S, Pierré A, Pfeiffer B, Monneret C, Dauzonne D.

Org Biomol Chem. 2005 Mar 21;3(6):1074-80. Epub 2005 Feb 18.


Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.

Smith PJ, Souès S, Gottlieb T, Falk SJ, Watson JV, Osborne RJ, Bleehen NM.

Br J Cancer. 1994 Nov;70(5):914-21.

Supplemental Content

Support Center